anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine; pharmacology.SUBSTANCE: invention refers to pharmacology and concerns a drug for treating oral diseases. What is presented is a medicinal agent in the form of a solution for preparing a spray for treating oral diseases, which contains a combination of two active components, excipients and a solvent. First active component is branched oligohexamethylene guanidine of formula,where R isor,n, nand nare equal to 1–3, a z is equal to 0.15–1.10 with molecular weight distribution M/Mfrom 5.4 to 9.3 with weight-average molecular weight Min the range from approximately 3,800 to 6,300 and number-average molecular weight Min the range from approximately 600 to 1100 in form of hydrochloride (OGMG-GC). Second active component is selected from benzalkonium chloride or benzoxonium chloride. Excipients include glycerol, menthol, sodium saccharinate, and the solvent is purified water or a mixture thereof with ethyl alcohol. Medicinal agent has the following composition (wt/vol. %): Osmag-GC 0.1–0.5; benzalkonium chloride 0.005–0.05 or benzoxonium chloride 0.01–0.02; glycerine 30–50; menthol 0.01–0.03; sodium saccharinate 0.03–0.06; solvent - up to 100.EFFECT: proposed drug is effective against a wide range of pathogenic microorganisms and can be used in dental and ENT practice.1 cl, 8 tbl, 10 ex
Autologous T Cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -9 - Day -4.
Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO, MUGA, CT and may undergo MRI and blood and urine sample collection on study.
PURPOSE:To prevent smelling of foreign odor or strong irritating smell when burning moxa by reducing the amount of a binder used when forming a sheet- shaped material by recycling waste powder of raw materials for moxa. CONSTITUTION:With 100 pts.wt. waste powder of raw materials for moxa, e.g. moxa lees, waste mugwort and powdery mugwort, 8 to 12wt.% binder, 1 to 12wt.% pulp fiber and 4 to 8wt.% humectant are mixed in the presence of water till the resultant mixture becomes uniform. The resultant wet material paste or slurry is formed into a sheet-shaped material of about 0.15 to 0.18mm thickness and the obtained sheet-shaped material is dried up to 11 to 12wt.% water content, thus producing the sheet-shaped moxa. As the binder, an aqueous solution of CMC, carboxymethylstarch, sodium alginate, polyvinyl alcohol, etc. is used.
A system is implemented to collect data from a plurality of different sources. The data comprises information about episodes experienced by a plurality of consumers. The system is configured to receive a cost estimate request from a user for a specified episode. The may access the data to determine a plurality of service items for the specified episode and the associated cost of each service item. An episode may be associated with one or many service items. The network-based service may generate a response to the cost estimate request. The response may include the plurality of service items determined for the specified episode and the associated cost information. The system may send the response to the user.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of trastuzumab or of other trastuzumab products.  
Among 903 women with metastatic breast cancer, human anti human antibody (HAHA) to trastuzumab was detected in one patient using an enzyme linked immunosorbent assay (ELISA). This patient did not experience an allergic reaction. Samples for assessment of HAHA were not collected in studies of adjuvant breast cancer.  
The clinical relevance of the development of anti-trastuzumab antibodies after treatment with trastuzumab is not known.
The purpose of this pilot study is to determine the safety and potential efficacy of sustained-release bupropion (Zyban®) for the treatment of nicotine dependence in patients with bipolar affective illness. we propose to conduct a preliminary study of the safety and efficacy of bupropion SR (with flexible dosing up to 300 mg/day) in comparison to placebo in medication-maintained and stabilized outpatients with bipolar I and II disorder who are currently depressed despite mood-stabilizing medication and who are also nicotine-dependent cigarette smokers, and who are motivated to quit smoking. Subjects will be n=32 subjects between 18 and 65 years of age who meet DSM-IV criteria for bipolar disorder (either Type I or II), and nicotine dependence, and smoke at least 15 cigarettes per day, with an FTND score at baseline \>5, expired breath CO \>10, and plasma cotinine \>150 ng/ml, and are motivated to quit smoking within thirty days of the initial intake. Subjects must be on a stable dose of a mood stabilizer (e.g. lithium, valproate, carbamezepine, topiramate, gabapentin or atypical antipsychotic), and be in complete remission from active manic or hypomanic and psychotic symptoms as judged by a psychiatric evaluation. Subjects will be recruited through outpatient departments at Connecticut Mental Health Center (CMHC) and its satellite clinics. Study medications will be given for 9 weeks duration, beginning at 1 week prior to the "quit date". Bupropion \[as the intermediate-release (IR) formulation\] will begin at 75 mg po qd x 3days, then increase to 150 mg \[as bupropion SR formulation\] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (the target quit date; TQD) as tolerated, and this dose will be continued for an additional eight (8) weeks at up to 150 mg po bid. We will allow flexible dosing above 150 mg/day to allow for adjustments needed if a bipolar subject does not tolerate the full dose of Zyban at 300 mg/day. Zyban will then be discontinued at the end of Week 10. Primary outcome measures are endpoint (7-day) smoking abstinence and adverse events.
PURPOSE: A composition for enhancing immunity containing Cudrania tricuspidata fruit extract is provided to promote splenocytes and macrophages and ensure immunity enhancement. CONSTITUTION: A composition for enhancing immunity contains Cudrania tricuspidata fruit extraction as an active ingredient. The Cudrania tricuspidata extract is isolated using water, low alcohol of C1-C4, or mixture solvent thereof. The low alcohol is ethanol or methanol. The Cudrania tricuspidata fruit is isolated through hot water extraction, ultrasonic wave extraction, or reflux extraction. An agent for preventing and treating diseases caused by immunity deterioration contains the Cudrania tricuspidata fruit extract as an active ingredient. The diseases caused by immunity deterioration are infectious diseases, inflammatory diseases, allergic disease such as atopy, chronic fatigue or cancer.
Monophthalmos means the best corrected visual acuity (BCVA) of the worse eye is less than 0.05 or the central visual field (CFOV) is less than 5°. The ocular surgery of the better eye in monophthalmic patients is of high risk. On the one hand the surgical failure will result in the patient falling into permanent darkness. On the other hand the monophthalmic patient may have the same disease in both two eyes such as high axial myopia, uveitis and glaucoma, which will increase the surgical risk. There is still no consensus on whether it is necessary to take risks to perform this kind of operation. In this study we will evaluate the change of psychological status before and after surgery in monophthalmic patients who receive the ocular surgery in eye with better vision. The necessity of the ocular surgery in monophthalmic patients will be evaluated from the point of social psychology.
The proposed study is a phase 2, open-label study of tofactinib in treatment of patients with chronic pouchitis. Subjects with chronic active pouchitis will be screened and recruited if they meet eligibility criteria. Eligible subjects will undergo baseline clinical evaluation, laboratory testing and a pouch endoscopy. They will then receive oral tofacitinib 10 mg twice daily for 8 weeks. Clinical and laboratory data will be collected at week 4 and week 8, and all subjects will undergo a end of treatment pouch endoscopy at 8 weeks. Clinical, laboratory and endoscopic data at 8 weeks will be compared to the baseline data to evaluate study outcomes.
The present invention relates to a feminine cleanser composition and a preparation method of the same. In particular, the present invention provides: a feminine cleanser composition formulated as an effervescent tablet, which comprises, as a main ingredient, a freeze-dried fermentation product prepared by fermenting, with Bacillus subtilis, a water extract of a mixture containing Phellodendron amurense Rupr., Lithospermum erythrorhizon Siebold & Zuccarini, Saururus chinensis (Lour.) Baill, and Chrysanthemum zawadskii var. latilobum (Maxim.) Kitam; and a preparation method of the same. The feminine cleanser composition according to the present invention has excellent deodorizing properties, moisturizing properties, and abilities to improve skin tone and skin firmness, as well as antibacterial properties; and does not use synthetic antibacterial agents, preservatives, or synthetic surfactants, and thus causes no skin irritation and shows excellent safety. Further, the feminine cleanser composition is slightly acidic, and thus can maintain a healthy vaginal environment; can be used on areas such as vulva or underarm of a woman to provide antibacterial action as well as to moisturize and improve skin tone and skin firmness; and has excellent portability and storability, and convenience of handling and use.
The primary symptom of visual snow syndrome (VSS) is the unremitting perception of small, flickering dots covering the visual field. VSS is a serious but poorly understood condition that can interfere with daily tasks. Several studies have provided qualitative data about the appearance of visual snow, but methods to quantify the symptom are lacking. Here, we developed a task in which participants with VSS adjusted parameters of simulated visual snow on a computer monitor until the simulation matched their internal visual snow. On each trial, participants (n = 31 with VSS) modified the size, density, update speed, and contrast of the simulation. Participants' settings were highly reliable across trials (intraclass correlation coefficients > 0.89), and they reported that the task was effective at stimulating their visual snow. On average, visual snow was very small (less than 2 arcmin in diameter), updated quickly (mean temporal frequency = 18.2 Hz), had low density (mean snow elements vs. background = 2.87%), and had low contrast (average root mean square contrast = 2.56%). Our task provided a quantitative assessment of visual snow percepts, which may help individuals with VSS communicate their experience to others, facilitate assessment of treatment efficacy, and further our understanding of the trajectory of symptoms, as well as the neural origins of VSS.
All studies will be carried out in a blind fashion according to FDA guidelines, which describes the number of subjects required to satisfy FDA guidelines and labeling requirements of sunscreens. Human subject selection: Healthy volunteers (n=25) free from systemic or dermatological disorders of Fitzpatrick skin type I, II or III (12 male and 13 female; ages 18 through 55) will be recruited. Rectangular test sites of (30 cm2) on the infrascapular area of the back will be delineated, and inspected to ensure uniform pigmentation, skin tone and texture, and absence of warts, moles, nevi, scars, blemishes and active dermal lesions. SPF determination: A 150 W Xenon Arc Solar Simulator, which produces a continuous UV spectra substantially equivalent to that of natural sunlight will be used and UVB radiation monitored continuously. Measurements will be recorded within 8 mm from the surface of the skin, and the size of the exposure site will be ≥ 0.5 cm2. The Sunscreen or a positive control (8% homosalate) will be applied to subjects evenly in the delineated areas at 2 mg/cm2. Following static exposures, test sample and water resistant controls will be applied on adjacent sites for testing. An unprotected site will receive a series of five UV exposures based upon the previously determined Minimal Erythemal Dose (MED). The UV exposures for each formulation, will be calculated from previously determined MED and the intended SPF. Immersion procedure: Immersion will be conducted in a whirlpool tub with room temperature water circulating at 3450 r.p.m. Following pre-immersion SPF measurements, volunteers will be subjected to 80 min of whirlpool immersion, with SPF measurements taken after air drying at 20, 40, and 80, min. c. Data Analysis and Interpretation: The 80 min time point is chosen as a benchmark for success because the FDA only permits finished sunscreen products to be labeled as water resistant for up to 80 min. All subjects will return to the laboratory sixteen to twenty-four hours post-exposure for a blinded determination of erythema responses, the mean SPF, standard deviation (s) value, and standard error (SE). No attempts to determine the influence of sex or age on the interpretation of results will be undertaken because of Phase I SBIR budgetary and time limitations, and because this is not a requirement of FDA or customers / distribution partners who will purchase the product. The standard deviation (s) will be determined and the upper 5% point was obtained from the t distribution table with n-1 degrees of freedom (t).
INTRODUCTION: Canada is in the midst of an overdose crisis. The use of prescription opioids in Canada has increased steadily over the past two decades, with stark increases in opioid-induced respiratory depression and related deaths. Opioids are the mainstay of treatment for cancer-related pain. Patients with cancer are not immune to the risks associated with opioid use but are underrepresented in available literature outlining risk mitigation strategies. Pharmacists are ideally placed to employ opioid risk mitigation practices to support safe and effective opioid use for patients with cancer-related pain. However, the current attitudes, confidence, and safety practices of pharmacists around how to best support these patients are not known.
METHODS: This study was a descriptive environmental scan of pharmacists who provide direct patient care in Canada. An electronic questionnaire was built using the web based Opinio software. It was distributed via email by several provincial and national pharmacy organizations and online platforms. The questionnaire consisted of Likert-scale and open-ended questions and was open to participants for a 6-week period from February 12th to March 23rd, 2020. Analysis was conducted using descriptive statistics and qualitative content analysis.
RESULTS: Eighty-one responses from pharmacists in nine provinces were included in the analysis. Respondents endorsed limited and varied practices when caring for patients receiving opioids for cancer-related pain. Further, they demonstrated wide ranging confidence and attitudes regarding opioid risk mitigation practices and beliefs. Less than 50% of pharmacists were aware of resources available for their patients with non-medical opioid use, and/or patients at high risk of opioid-induced respiratory depression. Education, resources, and communication were the most commonly reported perceived facilitators and barriers to resource use.
CONCLUSIONS: Pharmacists in Canada report employing opioid risk mitigation practices with low and varied frequency when caring for patients receiving opioids for cancer-related pain. They endorsed varied confidence and limited awareness of available provider and patient resources. These findings may help inform the development of new education models and evidence-based guidelines. New education models and evidence-based guidelines will support pharmacists in their pharmaceutical care of this vulnerable patient population, ultimately aiming to improve patient outcomes.
Abnormal movement patterns are one of the most challenging problems during rehabilitation of the patients with upper extremity injuries. They usually decrease the functional status of the upper extremity and prevent isolated muscle activations. Dysfunction of the kinetic chain system plays an important role in the development of these movement patterns. Thus, multi-segmental rehabilitation strategies has recently gained considerable importance in upper extremity rehabilitation. Core stabilization is one of the most popular rehabilitation approaches preferred to enhance functional stability of the kinetic chain system and dynamic postural alignment during activities. The purpose of this study is to determine the effects of core stabilization approach on functional status of the upper extremity and the amount of abnormal movement patterns. In addition, the factors affecting the abnormal movement patterns will be determined.
Research has consistently suggested that media consumption plays a vital role in children's socialization, including the socialization of painful experiences. Past research examining young children's popular media revealed worrisome trends in media depictions of pain; it consisted of narrow depictions of pain, gender stereotypes, and an overwhelming lack of empathy from observers, which could contribute to pain-related stigma. Research has not yet examined how pain is portrayed in adolescent media, despite adolescence being the developmental period when chronic pain often emerges. The current study extracted a cross-section of popular adolescent media selected based on popularity, including 10 movies and the first seasons of 6 TV shows. Pain instances were coded using 2 established observational coding schemes assessing sufferer pain characteristics and observer responses. Across 616 instances of pain, there was a preponderance of violence and injuries, whereas everyday, chronic-type, and medical/procedural pains were seldom represented. Individuals from marginalized (ie, gender diverse, girls) and minoritized groups (individuals with racialized identities) were underrepresented in pain instances. Furthermore, regardless of observed gender or "race," observers displayed a lack of empathy for sufferers and rarely engaged in prosocial behaviors. Popular media may serve as an agent of socialization in adolescence; thus, pain depictions may be a powerful force in propagating pain-related stigma and inequities. An opportunity exists to harness popular media to adaptively and accurately portray pain to adolescents.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, and can be used for treating furuncular abscess. For this purpose, a necrotic suppurative core is evaporated with a semiconductor laser in a selective coagulation mode to create a wound. 0.2-0.3 mg of a gel containing a mixture of photosensitiser photoditasine, biosoluble amphiphilic polymer specified in the group: sodium carboxymethyl cellulose, polyvinyl alcohol, chitosan sulphate and amphiphilic carrier additive - block copolymer of propylene oxide and ethylene oxide, are introduced in the wound. The ratio is as follows, wt %: photosensitiser 0.2-1.0; biosoluble polymer 93.0-97.8; carrier additive 2.0-6.0. After 20-30 minutes of exposition, the wound is managed with laser radiation at wave length 0.661 mcm and power density 20-30 J/cm2. Then, the wound is closed with an antiseptic-impregnated tissue. Starting the next day, the wound is processed with NO-containing gas flows once a day for 3-4 days at gas flow temperature 38C, distances 5 cm, expositions 50 sec and NO content - 500 ppm. ^ EFFECT: method allows higher clinical effectiveness, with decreased dystrophic and inflammatory processes due to complete removal of necrotic tissues, microcirculation disturbance in wound tissues, and formation of a thin cosmetic scar. ^ 2 ex
This review presents the current updated knowledge of the treatment of spondylolisthesis (SL). The prevalence of SL is dependent on age, gender, and race. Symptoms include lower back pain, radiating pain and neurological deficits. Treatment can be conservative or surgical. Most recent literature advocates surgical treatment after 3-6 months with the inadequate effect of conservative treatment. Diagnosis is obtained with an X-ray or CT. Suspected SL should be admitted to specialised examination by a spine surgeon since progression may lead to worsening in symptoms, and surgery improves life quaility.
UNLABELLED: Paeniclostridium sordellii hemorrhagic toxin (TcsH) and Clostridioides difficile toxin A (TcdA) are two major members of the large clostridial toxin (LCT) family. These two toxins share ~87% similarity and are known to cause severe hemorrhagic pathology in animals. Yet, the pathogenesis of their hemorrhagic toxicity has been mysterious for decades. Here, we examined the liver injury after systemic exposure to different LCTs and found that only TcsH and TcdA induce overt hepatic hemorrhage. By investigating the chimeric and truncated toxins, we demonstrated that the enzymatic domain of TcsH alone is not sufficient to determine its potent hepatic hemorrhagic toxicity in mice. Likewise, the combined repetitive oligopeptide (CROP) domain of TcsH/TcdA alone also failed to explain their strong hemorrhagic activity in mice. Lastly, we showed that disrupting the first two short repeats of CROPs in TcsH and TcdA impaired hemorrhagic toxicity without causing overt changes in cytotoxicity and lethality. These findings lead to a deeper understanding of toxin-induced hemorrhage and the pathogenesis of LCTs and could be insightful in developing therapeutic avenues against clostridial infections.
IMPORTANCE: Paeniclostridium sordellii and Clostridioides difficile infections often cause hemorrhage in the affected tissues and organs, which is mainly attributed to their hemorrhagic toxins, TcsH and TcdA. In this study, we demonstrate that TcsH and TcdA, but not other related toxins. including Clostridioides difficile toxin B and TcsL, induce severe hepatic hemorrhage in mice. We further determine that a small region in TcsH and TcdA is critical for the hemorrhagic toxicity but not cytotoxicity or lethality of these toxins. Based on these results, we propose that the hemorrhagic toxicity of TcsH and TcdA is due to an uncharacterized mechanism, such as the presence of an unknown receptor, and future studies to identify the interactive host factors are warranted.